Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 11/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3883477 | 0.81 | MEN1 (0.46) | SMN1; SMN2ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL3882356 | 0.80 | MAPK14 (0.40) | MAPK13MAPK12MAPK11MAPK14ALDH1A1 | |
| SCHEMBL8273815 | 0.79 | MAPK13 (0.41) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL5623831 | 0.79 | MAPK13 (0.38) | MAPK13MAPK12MAPK11MAPK14SMN1; SMN2 | |
| SCHEMBL3877913 | 0.79 | MAPK14 (0.61) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3877916 | 0.79 | MAPK14 (0.61) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3881146 | 0.77 | MAPK14 (0.59) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3881152 | 0.77 | MAPK14 (0.59) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3877428 | 0.77 | MAPK14 (0.61) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3876875 | 0.77 | MAPK13 (0.39) | MAPK13MAPK12MAPK11MAPK14CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | CLARK MICHAEL PHILIP | 2009-03-12 | — | — | US | disclosed |
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | CLARK MICHAEL PHILIP | 2009-03-12 | — | — | US | disclosed |
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | CLARK MICHAEL PHILIP | 2009-03-12 | — | — | US | disclosed |
| US-7482356-B2 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482356-B2 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482356-B2 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1682551-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005047287-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | IL1B, IL1A, IL1RN | MAPK13 2033/4885MAPK12 2453/4885MAPK11 2410/4885 |
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | IL1B, IL1A, IL1RN | MAPK13 2033/4885MAPK12 2453/4885MAPK11 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.